Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by wexworthon Jul 30, 2020 12:34am
129 Views
Post# 31341638

RE:RE:TFC1067 sales in year 1

RE:RE:TFC1067 sales in year 1

Under that scenario, means Sirona collects $8k USD per 10,000 units sold, or $8 million USD or around $10.5 million cdn per year. 

You have taken 40% of the agents and assumed they order stock at zero (non active members) and scaled the average orders by agent sales ranking category, which is very reasonable.

On the product launch, most agents will pick up a tube or so for themselves, a few for inventory, and likely push a few more for sales within a three month quarter. Again, reasonable. 

And that is for North American market, so figure that estimate for the other countries listed in the Rodan agreement, and you may have very conservatively 25-50% more revenue there to start - say $13-15 Million with growth from there. 

Add on China and 0.04% production for the Asia region, then numbers start to scale very fast. 

So for 1067 alone, we need Rodan to launch, we need a 0.04% product in approval development, and we need a considerable supplier base to keep pace with potential demand when it hits the market. If the product catches on, our arguments with management might shift to production logistics. Good place to be.

<< Previous
Bullboard Posts
Next >>